These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 34119900)

  • 1. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
    Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
    Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
    Bloch O; Han SJ; Cha S; Sun MZ; Aghi MK; McDermott MW; Berger MS; Parsa AT
    J Neurosurg; 2012 Dec; 117(6):1032-8. PubMed ID: 23039151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of extent of resection and recurrent surgery on clinical outcome and overall survival in a consecutive series of 170 patients for glioblastoma in intraoperative high field magnetic resonance imaging.
    Coburger J; Wirtz CR; König RW
    J Neurosurg Sci; 2017 Jun; 61(3):233-244. PubMed ID: 26149222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
    Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
    Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
    Drexler R; Schüller U; Eckhardt A; Filipski K; Hartung TI; Harter PN; Divé I; Forster MT; Czabanka M; Jelgersma C; Onken J; Vajkoczy P; Capper D; Siewert C; Sauvigny T; Lamszus K; Westphal M; Dührsen L; Ricklefs FL
    Neuro Oncol; 2023 Feb; 25(2):315-325. PubMed ID: 35868257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioblastoma surgery with and without intraoperative MRI at 3.0T.
    Napolitano M; Vaz G; Lawson TM; Docquier MA; van Maanen A; Duprez T; Raftopoulos C
    Neurochirurgie; 2014 Aug; 60(4):143-50. PubMed ID: 24975207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.
    Pessina F; Navarria P; Cozzi L; Ascolese AM; Simonelli M; Santoro A; Clerici E; Rossi M; Scorsetti M; Bello L
    J Neurooncol; 2017 Oct; 135(1):129-139. PubMed ID: 28689368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study.
    Pessina F; Navarria P; Cozzi L; Tomatis S; Riva M; Ascolese AM; Santoro A; Simonelli M; Bello L; Scorsetti M
    J Neurooncol; 2017 Jan; 131(2):377-384. PubMed ID: 27826681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Examination of the Role of Supramaximal Resection of Temporal Lobe Glioblastoma Multiforme.
    Glenn CA; Baker CM; Conner AK; Burks JD; Bonney PA; Briggs RG; Smitherman AD; Battiste JD; Sughrue ME
    World Neurosurg; 2018 Jun; 114():e747-e755. PubMed ID: 29555603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance.
    Kuhnt D; Becker A; Ganslandt O; Bauer M; Buchfelder M; Nimsky C
    Neuro Oncol; 2011 Dec; 13(12):1339-48. PubMed ID: 21914639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudoprogression in glioblastoma patients: the impact of extent of resection.
    Park HH; Roh TH; Kang SG; Kim EH; Hong CK; Kim SH; Ahn SS; Lee SK; Choi HJ; Cho J; Kim SH; Lee KS; Suh CO; Chang JH
    J Neurooncol; 2016 Feb; 126(3):559-66. PubMed ID: 26608521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma.
    Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A
    J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Role for Surgical Resection of Multifocal Glioblastoma? A Retrospective Analysis of 100 Patients.
    Friso F; Rucci P; Rosetti V; Carretta A; Bortolotti C; Ramponi V; Martinoni M; Palandri G; Zoli M; Badaloni F; Franceschi E; Asioli S; Fabbri VP; Rustici A; Foschini MP; Brandes AA; Mazzatenta D; Sturiale C; Conti A
    Neurosurgery; 2021 Nov; 89(6):1042-1051. PubMed ID: 34662898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extent of resection affects prognosis for patients with glioblastoma in non-eloquent regions.
    Kow CY; Kim BJH; Park TI; Chen JCC; Vong CK; Kim JY; Shim V; Dragunow M; Heppner P
    J Clin Neurosci; 2020 Oct; 80():242-249. PubMed ID: 33099354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers.
    Straube C; Combs SE; Bernhardt D; Gempt J; Meyer B; Zimmer C; Schmidt-Graf F; Vajkoczy P; Grün A; Ehret F; Zips D; Kaul D
    J Neurooncol; 2024 May; 168(1):49-56. PubMed ID: 38520571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.